AlloSeq HCT is a targeted NGS-based solution enabling precise measurement of engraftment following hematopoietic stem cell transplant. The latest innovation in chimerism testing that is able to determine the relative contribution of up to 3 genomes in a single sample i.e. up to two donors per recipient.

High sensitivity may provide earlier indication of release within an hour.

Earlier studies demonstrate that michrochimerism is a better indicator than mixed chimersim

Patients who demonstrated persistent microchimerism post-allogeneic HCT were associated with improved survival rates (42% vs. 10%) and earlier relapse rates (34% vs. 72%) as compared to patients with mixed chimerism.

This highly accurate NGS-based chimerism test enables precise patient monitoring and early detection of relapse.

Streamlined assay workflow provides consistent results with minimal hans-on time

Amplification & Sequencing 1-step, single, multiplexed PCR reaction Multiplex amplification of 202 loci (SNP) Sample indexing/barcoding Indexed library Test up to 48 samples/run 0.22% limit of detection Combinable with other AlloSeq NGS solutions in a single run

Detailed Analysis, Intuitive User Interface with final results in Less Than 24 hrs

Quality metrics on recipient timeline with shortcuts to access other screens Contamination metric for high confidence results Compare up to 3 genomes N-1 analysis capability Sort informative markers Enhanced batch screen life cycle review Compare recipient and donor side by side Donor management module Automated sample list imports capability from any LIMS system